ULTRA Clinical Case Studies
The ULTRA Embolic Device is being evaluated clinically for the embolization of hypervascular tumors and the embolization of blood vessels to occlude blood flow to control bleeding / hemorrhaging in the peripheral vasculature
Angiomyolipoma Tumor
ULTRA was used to embolize the feeding vessels to a large AML tumor arising from the left kidney. Follow-up imaging at 43 days post treatment confirmed the stability of the device. No adverse events were observed.
Pre-treatment CT image showing the tumor size and location.
Angiogram during delivery of the ULTRA Embolic Device.
Renal Cell Carcinoma Tumor
ULTRA was used to embolize a large, renal cell carcinoma tumor prior to nephrectomy. The embolic was found to successfully devascularize the region of the tumor in which it was delivered. MRI imaging 24 hours after the procedure confirmed devascularization of the embolized site. No adverse events were observed.
Pre-delivery digital subtraction angiogram of the tumor mass
Angiogram during delivery of the ULTRA Embolic Device
Data on file. Fluidx Medical Technology, Inc.
The ULTRA Embolic Device is under development and does not have marketing clearance or approval in any market at this time. For investigational use only.